We are proud to have taken part in one of the major projects in the IT and Banking field in Israel: Adv. Alon Tabak Aviram and Adv. Ben Baharav represented the first Israeli Digital Bank in its engagement with TCS – a member of TATA Group, that will develop and supply the bank’s technological infrastructure as part of the establishment of a Banking Services Bureau in Israel. See Article
Extremely proud of our client Plaqless Ltd. for its part in the new breakthrough technology designed to revolutionize oral health introduced by Colgate. The Colgate® Plaqless Pro Smart Electric Toothbrush just won the Innovation Award at the CES in Las Vegas in advance of a 2020 launch. Congrats to Colgate and the entire Plaqless team!! Plaqless are represented by Adv. Alon Tabak Aviram and Adv. Tamar Nesher. See Article
Together with the New Year, we are proud to be celebrating our Firm’s 25th Anniversary!
Grateful to all those who have been with us over the years. Here’s to many more!
Adv. Uri Barak and Adv. Stav Kedar of our firm represented SonicWall, a US cyber company, in a $10M financing round led by Sonicwall, in Perimiter 81, which develops technology for secure remote access to enterprise networks. See Article
Adv. Uri Nesher and Adv. Naomi Vestfrid of our firm represented Jerusalem Venture Partners (JVP) and the Israel National Initiative Association (ii2020), as part of ILAB group, composed of JVP, Israeli communications giant Mellanox Technologies Ltd., ii2020, and Haifa’s business development center Mati Haifa, in their winning bid in the competitive process initiated by the Israel Innovation Authority to develop technological innovation in Haifa. The group will receive a NIS 25 million grant for 4 years from the Israel Innovation Authority and will match that amount, reaching NIS 50 million, with the aim of promoting and integrating extensive technological entrepreneurial activity in Haifa, in the areas of digital health, energy, environment, advanced industry 4.0 and smart transport, and will also establish dedicated workspaces and acceleration programs. See Article
Adv. Uri Nesher of our firm represented Jerusalem Venture Partners (JVP) in a $10 million round of financing led by Flint Capital, in Loom Systems, the creator of the leading predictive AIOps platform which detects IT issues before traditional monitoring tools, by capturing logs, metrics, alerts and events, correlating and predicting IT issues before the business is impacted, while also delivering the insights and knowledge the frontline needs to resolve them quickly. See Article
Adv. Galia Suessking Speigel and Adv. Tal Levy of our firm represented our long time client, the Caesarea Assets Corporation in its transaction with Max Management Israel Ltd. (Max Stock), controlled by APAX Fund for the lease by Max Stock of approximately 10,000 sqm in the “HaEshel” Logistics Center at the Caesarea Business Park.
Adv. Gershon Shalom Winter, Adv. Tamar Nesher and Adv. Karin Abramovitz of our Firm represented Advanced Dicing Technologies Ltd. – an Israeli based electronics dicing equipment company in its acquisition by Chinese investment fund Neng Yang. See Article
We are proud to have taken part in one of the main innovative projects in the IT and Banking field in Israel. Adv. Alon Tabak Aviram and Adv. Ilan Sapir of our IT Department represented the Digital Bank in its engagement in the Ministry of Finance’s tender to establish a Services Bureau. In addition, Adv. Alon Tabak Aviram and Adv. Ilan Sapir are representing the Digital Bank in its engagement with its future Core-Systems and IT Supplier.
Our firm, supports and represents the Caesarea Edmond Benjamin De Rothschild Assets Corp. (2001) Ltd., in all areas of its activity, and recently, Adv. Galia Suesskind Spiegel and Adv. Mayan Miller of our Real Estate Department, represented the company in its transaction with Mazor Robotics Ltd., for the lease by Mazor of approximately 5,200 sqm in the “Ofek 12” buildings of the Caesarea Smart Business Park.
Adv. Alon Tabak Aviram and Adv. Ilan Sapir of our IT Department represented Bank Mizrahi Tefahot in a transaction for implementation of a new securities market core system. See Article
Adv. Menachem Tulchinsky, Adv. Amit Hirsch and Adv. Shira Efrati of our firm represented Teva Pharmaceutical Industries Ltd. in a motion for discovery prior to submission of a motion for filing a derivative action filed against Teva, under a claim that retirement grants paid by Teva to its former senior office holders are inconsistent with the Company’s Compensation Policy and the law. The District Court rejected the motion for discovery and accepted Teva’s claims in full, imposing legal and attorneys’ fees on the petitioner.
Our Firm supported the establishment of a one-of-a-kind archeological tourist project in Caesarea, which was officially opened in a ceremony attended by President Reuven Rivlin and Baroness Ariane de Rothschild. The opening was preceded by five years of excavation, conservation and reconstruction at great investment by the Edmond De Rothschild Foundation and performed by the Caesarea Edmond Benjamin De Rothschild Corporation, together with the Israel Antiques Authority and the Israel Nature and Parks Authority.
Adv. David Cohen and Adv. Lior Etgar of our firm represented Biond Biologics Ltd in a $17 million financing round led by Israel Biotech Fund and Harel Insurance & Finance Group, with participation of Celgene Corporation, (NASDAQ: CELG), the Japanese-Israeli fund, SBI JI Innovation Fund and existing investors. Biond Biologics is a drug discovery and development company focused on the field of immunotherapy, combining excellent science and out-of-the-box innovative thinking. See Article
Adv. Uri Nesher, Adv. Hila Faber and Adv. Daniel Shil Szriber of our firm represented Jerusalem Venture Partners (JVP) in a $22.5 million financing round led by JVP in Quali Systems, together with investments from existing investors Dell Ventures, Kreos Capital, Evergreen Ventures, Gemini Israel Ventures, and ORR Partners. Quali Systems is a software company focused on automation and orchestration software to deliver environments-as-a-service for digital transformation initiatives aligned with cloud, DevOps and Security. See Article
Adv. Galia Suesskind-Spiegel and Adv. Mayan Miller of our firm represented Caesarea Assets Corporation in the signing of a huge deal with China’s Fosun Pharmaceutical’s Israel-based subsidiary for a 10-year lease of approximately 11,000 m2 of the entire “Ofek 15” building being built by Caesarea Assets Corporation near the Caesarea train station. See Article
Uri Nesher of our firm represented Jerusalem Venture Partners (JVP) founder and chairman Erel Margalit, in an investment in Israeli foodtech start-up InnovoPro, the developer of a revolutionary technology designed to extract a 70% protein concentrate from chickpeas, as part of a $4.25M financing round led by the investment arm of Migros, Switzerland’s largest retailer, with additional investments by Bits x Bites, a Chinese VC that invests in food tech, Ran Tuttnauer, ID Capital from Singapore and Yara ventures from Spain. See Article
Adv. Uri Nesher and Adv. Aaron Shaw of our firm represented Jerusalem Venture Partners (JVP) in a $2 million seed financing round led by JVP in blockchain cybersecurity startup Valid Network Ltd., which develops enterprise software for securing smart contracts capable of identifying code vulnerabilities, possible loopholes, changes between versions, and abnormal activity to prevent fraud. Valid will also join JVP’s cybersecurity incubator, JVP Cyber Labs. See Article
Adv. Daniel Chinn and Adv. Mati Rosenbaum of our firm represented Hetz Ventures and Vertex Ventures Israel in a $7 Million seed funding round in Trigo Vision, an Israeli retail automation startup which uses in-store ceiling-mounted cameras to identify items picked by customers and create a no-checkout shopping experience. See Article
Adv. Gershon Shalom-Winter and Adv. Lana Tavor of our office represented RedHill Biopharma in negotiating a co-promotion agreement with Napo Pharmaceuticals, Inc., a subsidiary of Jaguar Health (NASDAQ: JAGX), granting RedHill the exclusive right to co-promote Mytesi® (an FDA-approved anti-diarrheal prescription drug indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on anti-retroviral therapy) in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS. See Press Release
Adv. Menachem Tulchinsky and Adv. Elad Mirvis of our firm represented the Edmond Benjamin de Rothschild Caesarea Foundation in the negotiation and consummation of the new agreement between the State of Israel and the Foundation, in the framework of which, inter alia, the cooperation agreement between the parties was extended until 2032, the Foundation will donate substantial amounts of up to NIS 1 billion for higher education projects in Israel over the next few years, and will continue to support the development of the Or-Yam neighborhood in Or Akiva in cooperation with the Israeli Land Authority.
Adv. Doron Stern, Adv. Benjamin Bekkerman and Adv. Mati Rosenbaum of our firm represented Optimove, makers of the Science-first Relationship Marketing Hub, in its acquisition of the DynamicMail business from PowerInbox, a leader in email real-time personalization and dynamic subscriber engagement. See Article
Adv. David Cohen, Adv. Gershon (Glenn) Shalom-Winter, Adv. Uri Barak, Adv. Alon Karniel, Adv. Elad Mirvis, Adv. Lior Etgar and Adv. Stav Kedar, with the assistance of interns Karin Abramovich and Eden Halpert, represented Orbotech in its acquisition by KLA-Tencor Corporation (NASDAQ: KLAC) in exchange for cash and stock which values Orbotech at an equity value of approximately $3.4 billion. See Press Release
Adv. Doron Stern of our firm talk on Privacy & Privatization at the recent TEDx BGU event at Ben Gurion University. For the video click here
Adv. Menachem Tulchinsky, Adv. Uri Barak, Adv. Elad Mirvis, Adv. Lior Etgar and Adv. Alon Nahear of our firm represented Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) in its $4.5 billion debt offering for qualified institutional investors under Rule 144A of the U.S. Securities Act and to Non-U.S. persons pursuant to Regulation S under the U.S. Securities Act. To read more about the offering – click here
Adv. Uri Nesher and Adv. Aaron Shaw of our firm represented Jerusalem Venture Partners (JVP) in its investment as part of a $21 million series C funding round, lead by JVP and Arrowroot Capital in Leadspace – who developed the first B2B Audience Management Platform for Marketing and Sales. See press release
Adv. Daniel Chinn and Adv. Saar Binyamin of our firm represented Lemonade Inc. in its recent $120,000,000 Series C financing round. See Press Release
Adv. Gershon Shalom-Winter and Adv. Lior Etgar of our firm represented an Israeli Hi-Tech company, specializing in laser and optical amplifiers, in an investment round in which the company raised approximately $14 million.
Adv. David Cohen, Adv. Lior Etgar and Adv. Aner Lev of our firm represented an Israeli biomed company which specializes in life science research and development in the field of cancer and autoimmune disorders, in its Series A Preferred Share investment round in which the company raised approximately $4.5 million.
Adv. Alon Tabak Aviram, Adv. Dafna Achiam Tal, Adv. Ilan Sapir and Adv. Alon Nahear of our firm represented Israeli company Nextine Ltd., a leading provider of industrial cyber security solutions, in its acquisition by Honeywell corporation for approximately $35 million. See press release
עדכוני חקיקה ופסיקה בדיני עבודה – יולי 2017 לחץ/י כאן למזכר
Adv. Daniel Chinn and Adv. Hila Faber of our firm represented Aleph VC in its investment as part of a $4 million seed round, with additional investment from XL Innovate, in Israeli rel time political risk evaluaion company Geoquant.
Adv. Daniel Chinn and Adv. Hila Faber of our firm represented Qumra Capital (Qumra) in its investment as part of a $22 million funding round led by Qumra, with additional investment from BRM Group and other European investors, in Israeli resort suite booking company Sweet Inn. See press release
Adv. Uri Nesher and Adv. Mati Rosenbaum of our firm represented Jerusalem Venture Partners (JVP) in its investment as part of a $6 million funding round led by JVP, with additional investment from Meron Capital and 31Ventures Global Innovation Fund, in Loom Systems Ltd., an Israeli AI-powered log analysis software platform developer. See press release
Adv. Gershon Shalom-Winter of our firm represented RedHill BioPharma Ltd. (NASDAQ/TASE: RDHL) in connection with the acquisition from Entera Health Inc. of exclusive rights in the U.S. to EnteraGam®, a commercially-available medical food, comprising a serum-derived bovine immunoglobulin/protein isolate (SBI), which must be administered under medical supervision. RedHill BioPharma is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal (GI) and inflammatory diseases and cancer. See Press Release
Adv. David Cohen, Adv. Uri Barak and Adv. Lior Etgar of our firm represented Israeli automatic print inspection systems company – Advanced Vision Technology Ltd. (XETRAL VSJ) in its acquisition by US technology company Danaher Corp for $100 million. AVT is the only Israeli company listed for trade on the Frankfurt Stock Exchange. See press release
OpenValley עו”ד גליה זיסקינד שפיגל ועו”ד מעין מילר ממשרדנו ייצגו את החברה לנכסי קיסריה, במו”מ על השכרת כל מבנה אופק 11 שפארק העסקים של קיסריה, לחממה הטכנולוגית
Adv. Gershon Shalom-Winter of our firm represented ConTIPI Medical Ltd., an Israeli developer of non-invasive, disposable solutions for pelvic floor dysfunction in women, in its Series A Preferred Share investment round in which it has raised almost $2,000,000.
Adv. Gershon Shalom-Winter of our firm represented RedHill BioPharma (NASDAQ/TASE: RDHL) in connection with an exclusive co-promotion agreement with a subsidiary of Concordia International Corp. (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, granting RedHill certain U.S. promotion rights for Donnatal. See Press Release